NCT06316557 (HOPE) is a NA clinical trial of iTBS group in Post-stroke Cognitive Impairment, sponsored by Zi-Xiao Li.

Who is sponsoring NCT06316557?

NCT06316557 is sponsored by Zi-Xiao Li.

What drugs are being tested in NCT06316557?

Interventions in NCT06316557: iTBS group, control group.

What condition does NCT06316557 study?

NCT06316557 studies Post-stroke Cognitive Impairment, Ischemic Stroke.

Is NCT06316557 still recruiting?

NCT06316557 is currently recruiting now. Last updated 2 July 2025.

Last reviewed 2025-07-02 · How we verify

NCT06316557: HOPE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HOPE From the Cerebellum: TMS-Induced Cognitive Recovery After Stroke

Recruiting now NA Last updated 2 July 2025

What this trial tests

NA trial testing iTBS group in Post-stroke Cognitive Impairment in 70 participants. Currently enrolling.

Timeline

1 January 2025

Primary endpoint
1 July 2026

1 April 2027

Quick facts

Lead sponsor	Zi-Xiao Li
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	70
Start date	1 January 2025
Primary completion	1 July 2026
Estimated completion	1 April 2027
Sites	1 location across China

Drugs / interventions tested

iTBS group
control group — full drug profile →

Conditions studied

Post-stroke Cognitive Impairment — all drugs for Post-stroke Cognitive Impairment →
Ischemic Stroke — all drugs for Ischemic Stroke →

Sponsor

Zi-Xiao Li

Who can join

18 and older, any sex, with Post-stroke Cognitive Impairment or Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this clinical trial is to investigate the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in the cerebellum for individuals with post-stroke cognitive impairment. Participants will undergo rTMS in the cerebellar hemisphere opposite the lesion site, once daily for a total of five days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06316557 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zi-Xiao Li
Last refreshed: 2 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06316557.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing